▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #542 by analyst upside · 2026-06-27
PASG
Passage Bio, Inc.
Healthcare · Market Cap $15M · P/E 0x
ANALYST PRICE TARGET
+169.5%
implied upside to consensus target
Current Price $4.7
Consensus Target $12.67
Bull Target $23.0
Bear Target $7.0
Analysts Covering 3
ANALYST CONSENSUS — BUY
Strong Buy
0
Buy
3
Hold
0
Sell
0
52-Week Low $3.29
52-Week High $20.0
YTD Return -59.8%
FUNDAMENTALS
Market Cap $15M
P/E Ratio (TTM) N/A
Forward P/E -0.5x
EPS (TTM) $-11.84
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $3.29
52-Week High $20.0
Current Price $4.7
Bear Target $7.0
Bull Target $23.0
● Now $4.7 ● Target $12.67
TRADING DATA
Avg Volume 111K
YTD Return -59.8%
Analyst Count 3
Consensus Buy
Upside to Target +169.5%
Last Updated 2026-06-27

ANALYST SUMMARY

Passage Bio, Inc. (PASG) is currently trading at $4.7 with a Wall Street consensus price target of $12.67, implying potential upside of 169.5% over the next 12 months. 3 analysts currently cover PASG, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $23.0, while the most cautious has a target of $7.0.

PASG operates in the Healthcare sector with a market capitalisation of $15M. The stock is down 59.8% year-to-date and is currently trading near the lower end of its 52-week range of $3.29 – $20.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

YCBD +187.7%
cbdMD, Inc.
$7M · P/E 0.3x · Strong Buy
NEPH +93.9%
Nephros, Inc.
$39M · P/E 45.1x · Strong Buy
XTNT +193.6%
Xtant Medical Holdings, Inc.
$59M · P/E 42.0x · Buy
DXR +124.5%
Daxor Corporation
$59M · P/E 6.1x · Strong Buy
BSEM +103.5%
BioStem Technologies, Inc.
$58M · P/E 3.9x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for PASG, with each firm's 90-day track record across all stocks we track. See full firm rankings →

TD Cowen ↓ Downgrade
Buy → Hold 2026-04-21 Building track record
Chardan Capital ↓ Downgrade
Buy → Neutral 2026-04-21 33% win rate (6 calls)
Oppenheimer — Reiterated
Outperform → Outperform 2026-04-21 14% win rate (7 calls)
Wedbush ↓ Downgrade
Outperform → Neutral 2026-04-21 Building track record
Oppenheimer ● Initiated
Outperform 2026-03-31 14% win rate (7 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2026-03-04 Building track record
Chardan Capital — Reiterated
Buy → Buy 2025-11-12 33% win rate (6 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2025-08-14 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →